-
公开(公告)号：US10444247B2
公开(公告)日：2019-10-15
申请号：US15512190
申请日：2015-09-11
申请人： Wallac Oy
摘要： The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNR1, P1GF2, Activin A, Ue3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.
-
2.发明申请公开(公告)号：US20190137508A1
公开(公告)日：2019-05-09
申请号：US16145650
申请日：2018-09-28
申请人： Wallac Oy
IPC分类号： G01N33/68
摘要： A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.
-
3.发明申请SYSTEM AND METHOD FOR DETERMINING RISK OF PRE-ECLAMPSIA BASED ON BIOCHEMICAL MARKER ANALYSIS 审中-公开基于生物化学标记分析的预处理风险的系统和方法公开(公告)号：US20140273025A1
公开(公告)日：2014-09-18
申请号：US13837134
申请日：2013-03-15
申请人： WALLAC OY
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N2333/47 , G01N2333/475 , G01N2333/515 , G01N2800/368 , G01N2800/50 , G16B40/00
摘要： A method for predicting risk of pre-eclampsia in a pregnant individual includes measuring one or more biochemical markers including an RBP4 biochemical marker in a blood sample obtained from the pregnant individual to determine one or more biomarker levels including an RBP4 biomarker level, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing pre-eclampsia.
摘要翻译： 用于预测怀孕个体中先兆子痫风险的方法包括在从怀孕个体获得的血液样品中测量一种或多种生物化学标志物，包括RBP4生物化学标记物，以确定一种或多种生物标志物水平，包括RBP4生物标志物水平，鉴定 所述一个或多个测量的生物化学标记中的每一个，所测量的生物标志物水平与相应的预定对照水平之间的差异，以及响应于所述鉴定，确定对应于具有或发展先兆子痫的孕妇的相对风险的预测。
-
4.发明申请公开(公告)号：US20180156815A1
公开(公告)日：2018-06-07
申请号：US15886698
申请日：2018-02-01
申请人： Wallac Oy
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N2333/7151 , G01N2333/8132 , G01N2800/042 , G01N2800/368 , G01N2800/54
摘要： A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.
-
公开(公告)号：US20170285041A1
公开(公告)日：2017-10-05
申请号：US15508135
申请日：2015-09-01
申请人： Wallac Oy
发明人： Tarja Ahola , Heikki Kouru , Mikko Sairanen
CPC分类号： G01N33/689 , G01N33/74 , G01N2333/70564 , G01N2800/368
摘要： The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.
-
公开(公告)号：US11255861B2
公开(公告)日：2022-02-22
申请号：US16552218
申请日：2019-08-27
申请人： Wallac Oy
IPC分类号： G01N33/68
摘要： The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNFR1, PIGF2, Activin A, uE3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.
-
公开(公告)号：US10656163B2
公开(公告)日：2020-05-19
申请号：US15508135
申请日：2015-09-01
申请人： Wallac Oy
发明人： Tarja Ahola , Heikki Kouru , Mikko Sairanen
摘要： The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.
-
8.发明申请SYSTEM AND METHOD FOR DETERMINING RISK OF DIABETES BASED ON BIOCHEMICAL MARKER ANALYSIS 审中-公开基于生物化学标记分析测定糖尿病风险的系统与方法公开(公告)号：US20140273024A1
公开(公告)日：2014-09-18
申请号：US13836256
申请日：2013-03-15
申请人： WALLAC OY
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N2333/8132 , G01N2800/042 , G01N2800/368 , G01N2800/54
摘要： A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.
摘要翻译： 用于预测怀孕个体的妊娠糖尿病（GDM）的风险的方法包括测量从怀孕个体获得的血液样品中的一种或多种生物化学标记物，以确定一种或多种生物标志物水平，其中一个或多个测量的生物化学标记物包括在 至少一个PAI-2和sTNFR1，鉴定所述一个或多个测量的生物化学标记中的每一个，测量的生物标志物水平与相应的预定控制水平之间的差异，并且响应于所述鉴定，确定对应于相对 怀孕个体患有或发展GDM的风险。
-
9.发明公开公开(公告)号：US20240361336A1
公开(公告)日：2024-10-31
申请号：US18647364
申请日：2024-04-26
申请人： Wallac Oy
发明人： Mikko Sairanen
CPC分类号： G01N33/6893 , G16H50/20 , G01N2333/4703 , G01N2333/58
摘要： Methods of detection of congenital heart defect (CHD) in a newborn human patient, are provided according to aspects of the present disclosure which include: performing an assay for one or more biomarkers of CHD selected from the group consisting of: soluble Suppression of Tumorigenicity 2 protein (sST2), and Galectin-3 in a dried blood sample obtained from the newborn human patient, thereby determining a level of one or both biomarkers present in the dried blood sample. The determined level of the biomarker(s) present in the dried blood sample is compared with a standard representing a normal newborn control without CHD, thereby determining whether the determined level is increased or decreased compared to the standard, wherein an increased level of one or both biomarkers present in the dried blood sample, compared with a standard representing a normal newborn control without congenital heart defect, indicates detection of CHD in the newborn human patient.
-
公开(公告)号：US11162955B2
公开(公告)日：2021-11-02
申请号：US16145650
申请日：2018-09-28
申请人： Wallac Oy
IPC分类号： G01N33/68
摘要： A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.012 秒)
